Skip to main content

Table 1 Baseline characteristics of the patients

From: Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study

N (%) or median (interquartile range)

 

Total n = 78

TDF/FTC n = 61

ABC/3TC n = 17

EFV n = 36

ATV/r n = 27

LPV/r n = 15

Sex: Male

71 (91%)

56 (91%)

15 (88%)

34 (94%)

22 (81%)

15 (100%)

Age, years

43 (34-47)

44 (35-49)

38 (32-43)

42 (34-46)

44 (35-48)

42 (33-55)

Body mass index

23 (22-24)

23 (22-25)

22 (21-24)

23 (22-25)

22 (21-25)

22 (21-24)

Current smokers

28 (36%)

25 (41%)

3 (18%)

14 (39%)

6 (22%)

8 (53%)

Viral hepatitis coinfection

6 (8%)

5 (8%)

1 (6%)

0

0

6 (40%)

Prior AIDS

7 (9%)

5 (8%)

2 (12%)

2 (6%)

1 (4%)

4 (27%)

CD4/mm 3

315 (217-409)

304 (190-384)

431 (330-512)

342 (262-402)

330 (263-446)

177 (72-299)

CD8/mm 3

959 (660-1345)

949 (656-1335)

1053 (762-1468)

981 (774-1240)

1111 (646-1506)

709 (454-1109)

CD4/CD8 ratio

0.30 (0.19-0.46)

0.28 (0.17-0.41)

0.49 (0.22-0.59)

0.33 (0.19-0.46)

0.29 (0.24-0.49)

0.16 (0.13-0.38)

Viral load (log 10 copies/mL)

4.6 (4.1-5.2)

4.7 (4.3-5.2)

4.4 (3.6-4.9)

4.8 (4.3-5.2)

4.4 (4-4.9)

5.1 (4.6-5.3)

Viral load > 5 log 10

36%

     
  1. TDF, tenofovir; FTC, emtricitabine; ABC, abacavir; 3TC, lamivudine; EFV, efavirenz; ATV/r, atazanavir/ritonavir; LPV/r, lopinavir/ritonavir.